Product
Nanatinostat + Valganciclovir
1 clinical trial
7 indications
Indication
EBV-Related PTLDIndication
EBV-related non-Hodgkin's lymphomaIndication
EBV-Positive DLBCLIndication
NOSIndication
Epstein-Barr Virus Associated LymphomaClinical trial
An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory LymphomasStatus: Recruiting, Estimated PCD: 2025-07-01